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Results
We investigated the interaction between purified soluble
guanylate cyclase (sGC) from beef lung and NO by time-
resolved spectroscopy in a time-range which encom-
passes eleven orders of magnitude, from 1 ps [1] to 0.1 s
[2]. After its dissociation from the heme, NO either
recombines geminately to the4 - c o o r d i n a t eh e m ew i t h i n
τG1 = 7 ps [1] (96 ± 1 % of the population) or exits the
heme pocket (4 ± 1 %), allowing the proximal histidine to
rebind within 62 ± 10 ps. Then, NO is distributed in two
approximately equal populations (~2 %). One geminately
rebinds to the 5-coordinate heme (τG2 = 6.5 ns) while the
other migrates into the solution. NO can rebind from the
solution (bimolecular rebinding, τB =0 . 2 5m sw i t h[ N O ]
= 20 µM), forming a 6-coordinate heme with a rate con-
stant of 2 x 10
8 M
-1 s
-1 (in vitro purified protein) very
close to that measured in platelets (3 × 10
8 M
-1s
-1) [3].
The cleavage of Fe-His bond and subsequent forma-
tion of 5-coordinate NO-heme occurs with different
time constants for NO which geminately rebinds (τ5C1 =
0.66 µs) and for NO which binds from the solution
(τ5C2 = 43 ms). Thus, because the same structural event
occurs with rates separated by more than 4 orders of
magnitude, we must infer that sGC is not in the same
structural state in both cases, with a different strain
exerted on the Fe-His bond. This allosteric transition
between both states occurs in the time range 0.66 µs <
τR < 250 µs in sGC after His rebinding and NO release.
Conclusion
Since the discovery that NO binds to the proximal heme
side in cytochrome c’ [4] (AXCP), several models of
sGC activation were proposed which include the binding
of NO to the proximal heme side despite the lack of
observation for such an activation step in sGC. After the
fast histidine rebinding in the picosecond range, we have
observed only four phases in the nano to millisecond
time range (assigned as indicated in Table 1). Thus,
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Table 1 Rates of the transitions observed in kinetics.
Transition Time constants Transition rates
Bimolecular NO binding to 5c-His τB = 0.25 ms; [NO]= 20 µM kB =2x1 0
8 M
-1s
-1
Conversion 6c-NO ® 5c-NO τ5C2 =4 3m s k5C2 =2 3s
-1
Geminate NO rebinding to 5c-His τG2 = 6.5 ns kG2 = 0.15 x 10
9 s
-1
Conversion 6c*-NO ® 5c*-NO τ5C1 = 0.66 µs k5C1 = 1.5 x 10
6 s
-1
His rebinding to 4c-heme τHis =6 2p s kHis = 1.4 x 10
10 s
-1
Geminate NO rebinding to 4c-heme τG1 =7p s kG1 = 0.13 x 10
12 s
-1
Structural relaxation sGC* ® sGC 0.66 µs < τR < 250 µs 4 x 10
3 s
-1 <kR <1.5 x 10
6 s
-1
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did not detect NO binding to the proximal side of sGC
heme despite the fact that NO shows the same geminate
rebinding to the 4-coordinate heme in sGC and AXCP
[5]. Our data can be described with a one-site model,
without phases assigned to dinitrosyl formation or to
NO proximal binding.
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Figure 1 Model describing the species and transitions involved in the time-resolved experiments. a: 5-c-His sGC in the resting state. b: 6-C sGC.
c: 5-c-NO sGC, in the activate state. d: 4-c sGC after NO dissociation. e: 5-c-His sGC still in the activated conformation, immediately after His105
rebinding. f: 6-c sGC in the activated state, immediately after NO geminate rebinding. The value adjacent to the letter label is the wavelength of
the species. The star at the right bracket in c, d, e denotes the activated state of sGC. The starting species of the kinetic measurements is c. The
time constants indicated are those measured and the corresponding rates are given in Table 1. In species d, NO is located within the heme
pocket whereas in species e, NO is located in another docking site in the protein.
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